Performance of HOWL Werewolf Therapeutics | 100.7% in 12m
Compare HOWL with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Werewolf Therapeutics with its related Sector/Index XBI
Performance Duell HOWL vs XBI
| TimeFrame | HOWL | XBI |
|---|---|---|
| 1 Day | -1.48% | 0.67% |
| 1 Week | -10.2% | 5.92% |
| 1 Month | 1.01% | 0.44% |
| 3 Months | -8.00% | 0.91% |
| 6 Months | 97.4% | 29.64% |
| 12 Months | 100.7% | 6.11% |
| YTD | 28.9% | 0.39% |
| Rel. Perf. 1m | 0.18 | |
| Rel. Perf. 3m | 6.61 | |
| Rel. Perf. 6m | 6.99 | |
| Rel. Perf. 12m | 7.04 |
Is Werewolf Therapeutics a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Werewolf Therapeutics (NASDAQ:HOWL) is currently (May 2024)
not a good stock to buy. It has a ValueRay Fundamental Rating of -47.83 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOWL as of May 2024 is 6.81. This means that HOWL is currently undervalued and has a potential upside of +13.88% (Margin of Safety).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOWL as of May 2024 is 6.81. This means that HOWL is currently undervalued and has a potential upside of +13.88% (Margin of Safety).
Is HOWL a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
Values above 0%: HOWL is performing better - Values below 0%: HOWL is underperforming
Compare HOWL with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -11.49% | 1.37% | 77.95% | 73.67% |
| US NASDAQ 100 | QQQ | -11.94% | 1.06% | 77.66% | 63.41% |
| US Dow Jones Industrial 30 | DIA | -11.42% | 1.06% | 82.39% | 83.08% |
| German DAX 40 | DBXD | -10.47% | 1.02% | 77.55% | 87.24% |
| UK FTSE 100 | ISFU | -11.02% | -2.59% | 83.41% | 91.92% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -11.41% | -2.39% | 95.48% | 111.84% |
| Hongkong Hang Seng | HSI | -14.89% | -7.82% | 98.32% | 114.78% |
| Japan Nikkei 225 | EXX7 | -12.83% | 3.14% | 81.61% | 80.98% |
| India NIFTY 50 | INDA | -9.91% | 0.34% | 78.85% | 73.93% |
| Brasil Bovespa | EWZ | -12.04% | -0.62% | 92.81% | 81.39% |
HOWL Werewolf Therapeutics vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -12.89% | 2.49% | 76.08% | 59.99% |
| Consumer Discretionary | XLY | -10.10% | 0.47% | 84.83% | 77.56% |
| Consumer Staples | XLP | -10.33% | -1.13% | 85.45% | 99.43% |
| Energy | XLE | -7.00% | 5.88% | 86.56% | 80.36% |
| Financial | XLF | -10.97% | 2.21% | 74.36% | 71.37% |
| Health Care | XLV | -10.90% | 2.28% | 86.22% | 93.09% |
| Industrial | XLI | -10.64% | 2.33% | 73.93% | 73.96% |
| Materials | XLB | -9.99% | 3.92% | 81.26% | 85.28% |
| Real Estate | XLRE | -10.64% | 4.53% | 88.56% | 98.24% |
| Technology | XLK | -12.32% | 1.75% | 78.37% | 64.07% |
| Utilities | XLU | -12.70% | -4.51% | 83.94% | 97.63% |
| Aerospace & Defense | XAR | -13.41% | -1.73% | 78.98% | 74.59% |
| Biotech | XBI | -16.13% | 0.57% | 67.72% | 94.56% |
| Homebuilder | XHB | -12.49% | 2.60% | 57.06% | 48.41% |
| Retail | XRT | -11.69% | 1.53% | 75.88% | 77.48% |
Does Werewolf Therapeutics outperform its market, is HOWL a Sector Leader?
Yes, over the last 12 months Werewolf Therapeutics (HOWL) made 100.67%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.11%.
Over the last 3 months HOWL made -8.00%, while XBI made 0.91%.
Yes, over the last 12 months Werewolf Therapeutics (HOWL) made 100.67%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.11%.
Over the last 3 months HOWL made -8.00%, while XBI made 0.91%.
| Period | HOWL | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 1.01% | 0.44% | -0.36% |
| 3 Months | -8.00% | 0.91% | 4.90% |
| 12 Months | 100.67% | 6.11% | 27.00% |